Kerrie Brady, OcuTerra CEO

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves go­ing ear­li­er than an­ti-VEG­Fs

When Brent Saun­ders took on the chair­man role on OcuTer­ra Ther­a­peu­tics’ board of di­rec­tors a few months ago — his first biotech gig since sell­ing Al­ler­gan to Ab­b­Vie — he drew at­ten­tion to a start­up that wasn’t quite ready for it. The web­site of­fered a glimpse of the lead­er­ship team, a lead drug, but not much else.

That’s chang­ing now.

OcuTer­ra is step­ping in­to the lime­light with the fi­nal close of a $35 mil­lion Se­ries B, which is de­signed to fund a Phase II tri­al of its lead eye drop and there­by nail down proof of con­cept for what it calls a non-in­va­sive op­tion for a siz­able swath of pa­tients at the ear­ly stages of di­a­bet­ic reti­nal dis­ease and wet age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.